YCBD
YCBD
AMEX · Pharmaceuticals

Cbdmd Inc

$0.42
+0.03 (+7.24%)
Financial Highlights (FY 2026)
Revenue
54.29M
Net Income
-5,774,707
Gross Margin
62.4%
Profit Margin
-10.6%
Rev Growth
-18.5%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 62.4% 62.4% 47.5% 47.5%
Operating Margin -11.3% -10.1% 13.5% 15.0%
Profit Margin -10.6% -10.1% 12.2% 13.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 54.29M 66.59M 3.60M 4.26M
Gross Profit 33.86M 41.53M 1.71M 2.02M
Operating Income -6,118,943 -6,753,800 486.9K 638.9K
Net Income -5,774,707 -6,373,848 438.1K 574.3K
Gross Margin 62.4% 62.4% 47.5% 47.5%
Operating Margin -11.3% -10.1% 13.5% 15.0%
Profit Margin -10.6% -10.1% 12.2% 13.5%
Rev Growth -18.5% -18.5% +16.0% +23.9%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 2.68M 3.44M
Total Equity — — 4.26M 4.18M
D/E Ratio — — 0.63 0.82
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -2,932,877 -3,417,013 810.0K 832.9K
Free Cash Flow — — 302.1K 332.0K